Seres Therapeutics vs Upstream Bio
MCRB and UPB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MCRB and UPB compare
Upstream Bio is the larger company, worth 11 times as much as Seres Therapeutics ($152M against $13.9M).
Seres Therapeutics grew revenue faster over the last twelve months (505% versus 2.5% for Upstream Bio).
Seres Therapeutics keeps more of each dollar of sales as profit, with a net margin of −2210% compared with −5712% at Upstream Bio.
Upstream Bio scores higher on the StockData Score (8 against 7 for Seres Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MCRB | UPB |
|---|---|---|
| Size and price | ||
| Market cap | $13.9M | $152M |
| Share price | $1.40 | $2.78 |
| Change, 1 year | −91.3% | −88.3% |
| Change, 5 years | −99.2% | – |
| Beta (5Y) | 1.00 | 1.28 |
| Employees | 66 | 75 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 1 | 1 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 6.5× (better) | 53.1× |
| P/B | 0.7× | 0.7× (better) |
| FCF yield | −460% | – |
| Growth | ||
| Revenue growth (TTM) | 505% (better) | 2.5% |
| Revenue growth, 5Y average | −52.7% | – |
| Net income growth (TTM) | −970% | – |
| EPS growth (TTM) | −931% | – |
| Profitability | ||
| Operating margin | −3657% (better) | −6116% |
| Net margin | −2210% (better) | −5712% |
| FCF margin | −3010% | – |
| Return on equity | −144% | −53.5% (better) |
| Return on invested capital | – | −846% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.65 | 20.45 (better) |
| Altman Z-score | −24.76 | 3.80 (better) |
| Piotroski F-score | 6 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 22.9% | 92.3% |
| Held by insiders | 2.3% | 8.6% |
| Insider net buying, 12 months | −$10.0K (better) | −$105K |
| Short interest, % of float | 3.5% | 7.1% |
Go deeper
- MCRB stock overview
- MCRB income statement
- MCRB valuation and score
- UPB stock overview
- UPB income statement
- UPB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.